Adiponectin as inflammatory biomarker of chronic obstructive pulmonary disease
Background: Systemic inflammation appears to be a major factor linking COPD to metabolic disorders as comorbidities. Obesity is considered a state of chronic, low-grade inflammation in which a greater production of pro-inflammatory cytokines overcomes the production of cytokines with anti-inflammato...
Saved in:
| Published in: | The Egyptian journal of chest diseases and tuberculosis Vol. 63; no. 3; pp. 583 - 587 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
01-07-2014
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: Systemic inflammation appears to be a major factor linking COPD to metabolic disorders as comorbidities. Obesity is considered a state of chronic, low-grade inflammation in which a greater production of pro-inflammatory cytokines overcomes the production of cytokines with anti-inflammatory properties. Aim of the work: To measure serum adiponectin (APN) level in COPD (obese and non obese) during stable and acute exacerbation stage and to evaluate its role as a biomarker of systemic inflammation Subjects and methods: This study was conducted on 88 subjects; 68 male smokers with COPD (34 stable and 34 exacerbated each group reclassified into [17 obese and 17 non-obese]) and 20 age and sex matched apparently healthy subjects as a control group. Serum APN level was measured with ELIZA. Ventilatory function testing and body mass index (BMI) were performed in all patients and control subjects. Results: Serum APN level was approximately more than 3-fold higher in non-obese AECOPD and stable COPD cases than obese. However, more than 2-fold higher in non-obese control than obese. There was no correlation between adiponectin and FEV1, FEV1/FVC in COPD patients. Conclusion: Serum adiponectin level was raised in non-obese COPD cases more than obese COPD cases and the rise is more during exacerbation. In addition, serum adiponectin level was raised in obese COPD cases during exacerbation and during stable conditions. A further rise in serum APN in exacerbation period denotes that APN may also be a biomarker of exacerbation and represents significant prognostic marker for COPD disease. |
|---|---|
| ISSN: | 0422-7638 |
| DOI: | 10.1016/j.ejcdt.2014.02.006 |